Clinical Trials
Multidisciplinary Melanoma Clinic (MMC) Trials for Stage II (cutaneous), Stage III (nodal), and Stage IV disease (visceral metastasis)
Stanford is an active participant in the Eastern Cooperative Oncology Group multicenter clinical trials for melanoma.
Currently Available:
- Phase III Randomized Adjuvant Study of High Dose Interferon Alfa-2b Therapy in Patients with Stages IIA, IIB, and IIIA Melanoma (ECOG 1697)
[Purpose: To determine the effectiveness of one month of intravenous, high-dose interferon alfa in treating patients with stage IIA, IIB, IIIA melanoma that has been completely excised]
- Placebo-Controlled Phase III Trial of GM-CSF vs. Peptide Vaccination vs. GM-CSF + Peptide vs. Placebo After Complete Resection of "Locally Advanced" and/or Stage IV Melanoma (ECOG 4697) [Study closed to accrual October 31, 2006]
[Purpose: To determine the effectiveness of immune-based therapies GM-CSF and/or peptide vaccination in the treatment of patients with "locally advanced" or stage IV melanoma which has been completely removed surgically]
- E1602: A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma
[Purpose: To determine the cytotoxic T cell (CTL) response to each of 12 melanoma peptides in vaccinated patients with or without helper peptides. To estimate the rates of clinical response and survival, in patients vaccinated with a multi-peptide vaccine vaccine consisting of epitopes for CTL alone, epitopes for T-helper cells alone, or both]
- E2603: A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib (BAY 43-9006) versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma
[Purpose: To study chemotherapeutic agents (carboplatin and paclitaxel) alone and in combination with sorafenib (a targeted B-RAF inhibitor), to assess response in patients with unresectable stage III or IV melanoma]